<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00116402</url>
  </required_header>
  <id_info>
    <org_study_id>13426B</org_study_id>
    <nct_id>NCT00116402</nct_id>
  </id_info>
  <brief_title>A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations</brief_title>
  <official_title>A Pilot Study of the Mechanism of Synergism Between Fluticasone (FP) and Salmeterol in Preventing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the blood and airway of subjects with mild to
      moderate COPD while undergoing standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our objective is to examine the mechanism of the additive/synergistic properties of
      b2-adrenoceptor stimulation and corticosteroid receptor activation in:

        -  Preventing neutrophil adhesion to specific endothelial ligands, e.g. ICAM-1 and

        -  Undergoing activation as a consequence of this adhesion.

      We hypothesize that combination therapy with salmeterol + fluticasone (FP) will:

        -  Augment the inhibition of adhesion of neutrophils obtained from the peripheral blood of
           study subjects in vitro, by blocking gIV-PLA2 translocation to the nuclear membrane as
           for eosinophils;

        -  Augment the inhibition of transendothelial migration of neutrophils into airways of
           subjects with chronic obstructive pulmonary disease;

        -  Augment the numbers and concentrations of pro-inflammatory products in the
           bronchoalveolar lavage fluid; and

        -  Decrease the number of neutrophils in the bronchial tissue of endobronchial biopsies of
           treated patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate blood and airway neutrophil population in COPD patients by examining adhesion and migration in patients with mild to moderate COPD</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>salmeterol 50 mcg BID then crossover to combination therapy with fluticasone 220 mcg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone and salmeterol</intervention_name>
    <description>will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID
will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females &gt; 50 years of age

          -  Physiologic evidence of COPD defined per ATS guidelines as: cigarette smoking history
             &gt;20 pack years, FEV1/FVC &lt;70%

          -  Patients must have a post-bronchodilator FEV1 &gt;50% of predicted value at enrollment

          -  Patient must have an O2 saturation measure by pulse oximetry &gt;90% on RA

          -  Must be able to participate in the study, willing to give informed consent, and comply
             with the study restrictions

        Exclusion Criteria:

          -  Women of child-bearing potential defined as females who are less than 5 years post
             menopausal unless they have had a hysterectomy or bilateral oophorectomy

          -  Observation of any solitary nodule in the lung requiring further medical intervention

          -  Patients on maintenance therapy with oral steroids

          -  Patients with giant bullous disease

          -  Significant other medical conditions, which in the opinion of the investigator, will
             interfere with the patient's ability to perform the study tests

          -  Presence of a coagulopathy as defined by a platelet count &lt;100,000/mm3, and PT and PTT
             &gt;1.2 x the upper limit of normal

          -  Concurrent enrollment or participation in any other clinical trials within the past 30
             days

          -  Primary diagnosis of asthma

          -  History of alpha 1 antitrypsin deficiency

          -  Any clinically significant and active pulmonary disease that could contribute to
             dyspnea

          -  Current systemic and inhaled steroids and theophylline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imre Noth, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine, Pulmonary &amp; Critical Care Section, The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med. 2003;2(1):67-74.</citation>
    <PMID>14720023</PMID>
  </reference>
  <reference>
    <citation>Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003 Sep;124(3):834-43.</citation>
    <PMID>12970006</PMID>
  </reference>
  <reference>
    <citation>Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med. 2002 Jun 15;165(12):1592-6.</citation>
    <PMID>12070058</PMID>
  </reference>
  <reference>
    <citation>Kim KP, Rafter JD, Bittova L, Han SK, Snitko Y, Munoz NM, Leff AR, Cho W. Mechanism of human group V phospholipase A2 (PLA2)-induced leukotriene biosynthesis in human neutrophils. A potential role of heparan sulfate binding in PLA2 internalization and degradation. J Biol Chem. 2001 Apr 6;276(14):11126-34. Epub 2000 Dec 15.</citation>
    <PMID>11118430</PMID>
  </reference>
  <reference>
    <citation>Kim YJ, Kim KP, Han SK, Munoz NM, Zhu X, Sano H, Leff AR, Cho W. Group V phospholipase A2 induces leukotriene biosynthesis in human neutrophils through the activation of group IVA phospholipase A2. J Biol Chem. 2002 Sep 27;277(39):36479-88. Epub 2002 Jul 17.</citation>
    <PMID>12124392</PMID>
  </reference>
  <reference>
    <citation>Chang PS, Absood A, Linderman JJ, Omann GM. Magnetic bead isolation of neutrophil plasma membranes and quantification of membrane-associated guanine nucleotide binding proteins. Anal Biochem. 2004 Feb 15;325(2):175-84.</citation>
    <PMID>14751252</PMID>
  </reference>
  <reference>
    <citation>Myou S, Zhu X, Boetticher E, Myo S, Meliton A, Lambertino A, Munoz NM, Leff AR. Blockade of focal clustering and active conformation in beta 2-integrin-mediated adhesion of eosinophils to intercellular adhesion molecule-1 caused by transduction of HIV TAT-dominant negative Ras. J Immunol. 2002 Sep 1;169(5):2670-6.</citation>
    <PMID>12193740</PMID>
  </reference>
  <reference>
    <citation>Reumaux D, de Boer M, Meijer AB, Duthilleul P, Roos D. Expression of myeloperoxidase (MPO) by neutrophils is necessary for their activation by anti-neutrophil cytoplasm autoantibodies (ANCA) against MPO. J Leukoc Biol. 2003 Jun;73(6):841-9.</citation>
    <PMID>12773517</PMID>
  </reference>
  <reference>
    <citation>Zhu X, Muñoz NM, Kim KP, Sano H, Cho W, Leff AR. Cytosolic phospholipase A2 activation is essential for beta 1 and beta 2 integrin-dependent adhesion of human eosinophils. J Immunol. 1999 Sep 15;163(6):3423-9.</citation>
    <PMID>10477614</PMID>
  </reference>
  <reference>
    <citation>Meliton AY, Muñoz NM, Liu J, Lambertino AT, Boetticher E, Myo S, Myou S, Zhu X, Johnson M, Leff AR. Blockade of LTC4 synthesis caused by additive inhibition of gIV-PLA2 phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils. J Allergy Clin Immunol. 2003 Aug;112(2):404-10.</citation>
    <PMID>12897749</PMID>
  </reference>
  <reference>
    <citation>Reid DW, Ward C, Wang N, Zheng L, Bish R, Orsida B, Walters EH. Possible anti-inflammatory effect of salmeterol against interleukin-8 and neutrophil activation in asthma in vivo. Eur Respir J. 2003 Jun;21(6):994-9.</citation>
    <PMID>12797494</PMID>
  </reference>
  <reference>
    <citation>Qiu Y, Zhu J, Bandi V, Atmar RL, Hattotuwa K, Guntupalli KK, Jeffery PK. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003 Oct 15;168(8):968-75. Epub 2003 Jul 11.</citation>
    <PMID>12857718</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2005</study_first_submitted>
  <study_first_submitted_qc>June 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2005</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Chronic Obstructive</keyword>
  <keyword>Pulmonary Disease</keyword>
  <keyword>Inhaled Corticosteroids</keyword>
  <keyword>Airway Inflammation</keyword>
  <keyword>Bronchoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

